PFSA: Profusa, Inc Company Buyout Price

Revenue delay risks stemming from slow regulatory approvals and funding shortages amid costly testing are putting pressure on Profusa Inc (PFSA). This chart reflects a market valuation of 13.75. Profusa Inc (PFSA) is expanding B2B sales of Lumee systems for clinics by implementing oxygen sensors. Its competitive edge lies in developing biosensors that integrate with body tissues, eliminating rejection and enabling the monitoring of glucose levels for years.

PFSA profusa.com Real Price to Acquire Entire Company (11/23/2025 - 10/27/2026)

Financial and market metric breakdowns for Profusa Inc (PFSA)

- price and consensus price forecast:
Quote Chart Profusa Inc.|PFSA - Price Target Chart
- market capitalization data:
Market Capitalization Profusa|PFSA - Enterprise Value
- book capitalization data:
Book Value per Share Profusa|PFSA - Company Net Assets|Market Cap to Book Value Multiple profusa.com|PFSA - Company Total Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Profusa Inc|PFSA - Long-Term Debt to Capital|Current Liabilities to Capital profusa.com|PFSA - Company Debts|Debt to Net Assets Ratio Profusa
Comprehensive company analysis:PFSA (Profusa Inc.)

For a comparative asset analysis, an investor evaluates the total business value, moving beyond market capitalization. This metric sums the equity value with net debt, excluding cash. For Profusa Inc (PFSA), which develops innovative biosensors, this reflects the actual cost of acquiring a technological leader in preventive diagnostics. The current value of 13.75 allows for a comparison between the company's price and its potential. The dynamics of enterprise value levels help identify the risk of overpayment in a timely manner.

Who Profusa Inc competes with

DexCom Inc - Full Business Value|Total Company Value PEN (Penumbra Corp)|NOVT - Company Buyout Price|HAE: Enterprise Value|Enterprise Value inspiresleep.com|PROCEPT BioRobotics Corporation (PRCT) - Real Price to Acquire Entire Company|Aggregate Business Value CONMED Corp|Pulse Corp (PLSE) - Enterprise Value|Value Adjusted for Debt and Cash InMode MD (INMD)|PMI: Enterprise Value|surmodics.com - Total Enterprise Value|Total Company Value Senseonics Holdings (SENS)|NPCE - Value Adjusted for Debt and Cash|TCMD: Enterprise Value|SNWV (SANUWAVE Health Inc) - Enterprise Value|Total Company Value Outset Medical, Inc. OM|Full Business Value Electromed Inc|LENSAR - Enterprise Value|Total Enterprise Value AVITA Medical Inc. RCEL|Real Price to Acquire Entire Company PROF (Profound Medical)|BDMD - Enterprise Value|Real Price to Acquire Entire Company EDAP Medical EDAP|APYX - Aggregate Business Value|icecure-medical.com - Enterprise Value|Pulmonx (LUNG) - Company Buyout Price|Enterprise Value TELA|Real Price to Acquire Entire Company CytoSorbents Corp. (CTSO)|Sensus Healthcare, Inc. (SRTS) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash ZYXI (zynex.com)|electroCore - Total Company Value|Real Price to Acquire Entire Company Vicarious Surgical Inc RBOT|IINN (Inspira Technologies Oxy B.H.N. Ltd) - Enterprise Value|ICU - Total Enterprise Value|Enterprise Value iridex.com|Intelligent Bio Solutions Inc. (INBS) - Business Value|XAIR: Enterprise Value|Company Buyout Price STRATA Skin|Enterprise Value GCTK (GlucoTrack, Inc.)|Real Price to Acquire Entire Company nanovibronix.com (NAOV)|Enterprise Value VERO (Venus Concept Inc.)|nuwellis.com - Enterprise Value|AEMD - Total Company Value|Asensus Surgical, Inc. (ASXC) - Total Company Value|Real Price to Acquire Entire Company Avinger, Inc AVGR|BioSig (BSGM) - Value Adjusted for Debt and Cash|Enterprise Value CUTR (Cutera, Inc.)|Total Enterprise Value KNW|NARI: Total Company Value|Full Takeover Company Value Nevro Corp NVRO|Real Price to Acquire Entire Company RSLS (ReShape Lifesciences Inc.)|Enterprise Value Silk Road Medical Inc SILK